Viking Therapeutics Q4 loss widens on higher expenses but beats estimates
Viking Therapeutics (VKTX) Wednesday posted a wider net loss for the fourth quarter of 2018, owing to a sharp increase...
Health Care
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as...
Aurora Cannabis appoints activist billionaire investor Nelson Peltz as strategic advisor
Aurora Cannabis (ACB) stock surged more than 10% in the pre-market trading as the company appointed activist investor Nelson Peltz...
Earnings: Trevena slips on wider-than-expected Q4 loss
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market...
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the...
Avid Bioservices stock jumps after Q3 loss narrows on higher revenues
Avid Bioservices (CDMO) reported a narrower net loss for the third quarter of 2019, aided by a sharp increase in...
Viking Therapeutics earnings preview: All eyes on NASH
Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours....
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after...
Tilray rides on successful cannabis harvest in Europe
Tilray’s (TLRY) stock made strong gains early Wednesday after the Canadian marijuana giant said its European arm had a very...
Aurora Cannabis dethrones Canopy Growth as Cowen’s top pot stock
Research firm Cowen on Tuesday named Aurora Cannabis (ACB) its top stock pick for the marijuana industry, replacing Canopy Growth...
La Jolla Pharma stock declines after reporting Q4 earnings results
La Jolla Pharmaceutical Company (LJPC) reported its Q4 and full-year 2018 results after the market closed today. The company reported...
Biogen buys Nightstar, eyeing a bigger pie in ophthalmic gene therapy
Continuing the efforts to diversify into new areas of drug development, Biogen (BIIB) this week clinched an important deal that...
Portola Pharmaceuticals rises on strong Q4 earnings
Shares of Portola Pharmaceuticals (PTLA) gained 5.6% during pre-market trading on Friday, after the company posted a loss of $1.04...
Earnings: Dentsply Sirona Q4 profit beats despite revenue drop; stock jumps
Dentsply Sirona (XRAY), a provider of dental products and technology, reported a decline in earnings and revenues for the fourth...
Celgene stock takes a dive after major Bristol-Myers stakeholder opposes merger deal
It’s was a wild day for big pharma after Celgene Corp (CELG) slid at least 8% on early Thursday trade...
Trending stocks: Tandem Diabetes, Weight Watchers, MercadoLibre and more
TOP GAINERS Tandem Diabetes Care (TNDM) on Tuesday said its COO John Sheridan will take over as the CEO of...
Amarin’s stock gains after Q4 revenues beat expectations
Amarin Corporation (AMRN) surpassed analysts’ expectations on revenues for the fourth quarter of 2018 while net loss came in higher-than-expected....
Mylan stock tanks on Q4 earnings miss; issues full-year guidance
Shares of Mylan NV (MYL) fell sharply Tuesday after the specialty pharmaceuticals company reported a decline in its fourth-quarter earnings...
GW Pharma stock rises after reporting earnings results for the quarter ended Dec. 31, 2018
As GW Pharmaceuticals (GWPH) moved its fiscal year beginning to January 1, 2019, the company reported financial results for the quarter...
Aurora Cannabis to start production in Portugal
In line with its strategy to achieve an early-mover advantage in as many new markets as possible, Canadian marijuana giant...
Zynerba Pharmaceuticals stock soars on receiving US patent for its CBD gel to treat Fragile X syndrome
Cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) received US patent named “Treatment of Fragile X Syndrome with Cannabidiol”. Shares of Zynerba soared...